- Home
- ITRM
as 07-26-2024 4:00pm EST
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
| Founded: | 2015 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 26.6M | IPO Year: | 2018 |
| Target Price: | $6.00 | AVG Volume (30 days): | 283.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.62 - $2.50 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Iterum Therapeutics plc (ITRM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dunne Michael W. | ITRM | Director | Dec 22 '23 | Buy | $1.40 | 25,000 | $35,000.00 | 113,754 | SEC Form 4 |
| Dunne Michael W. | ITRM | Director | Dec 18 '23 | Buy | $1.84 | 10,000 | $18,442.00 | 88,754 | SEC Form 4 |
| Dunne Michael W. | ITRM | Director | Nov 22 '23 | Buy | $2.03 | 20,000 | $40,690.00 | 78,754 | SEC Form 4 |
| Fishman Corey N. | ITRM | Chief Executive Officer | Nov 20 '23 | Buy | $1.59 | 10,000 | $15,863.00 | 54,449 | SEC Form 4 |
Latest Iterum Therapeutics plc News
ITRM Breaking Stock News: Dive into ITRM Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Iterum Therapeutics Starts Rights Offering
GlobeNewswire
5 days ago
Iterum Therapeutics Commences Rights Offering
MT Newswires
a month ago
Iterum Therapeutics' New Drug Application for Sulopenem Referred to FDA Advisory Committee
GlobeNewswire
a month ago
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
GlobeNewswire
2 months ago
Iterum Therapeutics to Present Data at ASM Microbe 2024
GlobeNewswire
2 months ago
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Thomson Reuters StreetEvents
2 months ago
Q1 2024 Iterum Therapeutics PLC Earnings Call
GlobeNewswire
2 months ago
Iterum Therapeutics Reports First Quarter 2024 Financial Results
Compare ITRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITRM Iterum Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.